

Yageo Corp. (2327.TW)

Elevated UTR to meet with strong demand in 2H26, along with ongoing capacity expansion; Buy, with new TP of NT\$1,280

2327.TW 12m Price Target: **NT\$1,280.00** Price: **NT\$507.00** Upside: **152.5%**

Yageo hosted its 2Q26 result call on July 29th, with key takeaways including:

(1) Yageo guided that the UTR for both standard and premium product is expected to increase to 90%+ in 3Q26 from 80-85%/85+% in 2Q26 to meet with the strong demand. The company guided that revenue/GM/OPM in 3Q26 will all see a slight QoQ increase.

(2) UTR remains full for overall capacity thus the company will continue to expand capacity across all production lines (including Kaohsiung, Mexico, Vietnam, Suzhou, etc), with greater focus on expanding MLCC and tantalum capacitors capacity. The company mentioned that several CAPEX plans are already in the pipeline, which will gradually increase capacity on a quarterly basis in the coming quarters.

(3) The company has noted increasing customer interest in entering LTA to secure longer-term supply, with demand for LTAs are more focused on MLCCs and tantalum capacitors. Customers showing stronger interest are primarily those experiencing higher growth driven by AI.

(4) Management mentioned that BB ratio continue to improve on a monthly basis throughout 2Q26 and reached 2.2 by end of June (was at 1.0+ in 1Q26), which is one the factors that is showing positive sign of better demand in 2H26.

(5) Yageo mentioned its AI revenue exposure reached 16% in 2Q26 (up from 14-15% in 1Q26), which is tracking ahead of previous target of reaching 15% in 2026, demonstrating strong outlook with AI-related business.

(6) Management is seeing signs of a ramp in demand for high-capacitance capacitors driven by next-generation AI servers. As production capacity shifts toward high-end capacitors, supply of

BUY

Chao Wang

+886(2)2730-4195 | kuan-chao.wang@gs.com
Goldman Sachs (Asia) L.L.C., Taipei Branch

Allen Chang

+852-2978-2930 | allen.k.chang@gs.com
Goldman Sachs (Asia) L.L.C.

Daiki Takayama

+81(3)4587-9870 | daiki.takayama@gs.com
Goldman Sachs Japan Co., Ltd.


Key Data

Market cap: NT\$1.0tr / \$32.1bn
Enterprise value: NT\$1.1tr / \$33.4bn
3m ADTV: NT\$40.9bn / \$1.3bn
Taiwan
Taiwan Electronic Components
M&A Rank: 3
Leases incl. in net debt & EV?: No

GS Forecast

	12/25	12/26E	12/27E	12/28E
Revenue (NT\$ mn) New	132,930.0	178,007.0	239,623.0	325,553.6
Revenue (NT\$ mn) Old	132,930.0	196,764.5	289,670.6	388,444.8
EBITDA (NT\$ mn)	39,634.5	58,384.2	90,766.9	136,848.9
EPS (NT\$) New	11.51	19.01	31.27	49.20
EPS (NT\$) Old	11.51	21.22	37.56	57.32
P/E (X)	13.4	26.7	16.2	10.3
P/B (X)	1.9	5.5	4.7	3.9
Dividend yield (%)	3.9	2.0	3.2	5.1
CROCI (%)	9.5	12.5	18.7	27.3
	6/26	9/26E	12/26E	3/27E
EPS (NT\$)	4.59	5.02	5.50	6.26

GS Factor Profile



Source: Company data, Goldman Sachs Research estimates.
See disclosures for details.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

BUY

Yageo Corp. (2327.TW)

Rating since Jun 22, 2020

Ratios & Valuation

	12/25	12/26E	12/27E	12/28E
P/E (X)	13.4	26.7	16.2	10.3
P/B (X)	1.9	5.5	4.7	3.9
FCF yield (%)	7.8	3.3	4.9	7.9
EV/EBITDAR (X)	9.6	18.6	11.6	7.3
EV/EBITDA (excl. leases) (X)	9.6	18.6	11.6	7.3
CROCI (%)	9.5	12.5	18.7	27.3
ROE (%)	14.3	21.6	31.3	41.3
Net debt/equity (%)	35.8	21.0	4.1	(14.6)
Net debt/equity (excl. leases) (%)	35.8	21.0	4.1	(14.6)
Interest cover (X)	10.4	15.8	26.3	41.3
Days inventory outst, sales	81.6	62.9	50.0	45.1
Receivable days	76.3	76.3	78.4	78.1
Days payable outstanding	71.1	65.9	64.8	64.4
DuPont ROE (%)	13.6	20.2	28.7	37.1
Turnover (X)	0.3	0.4	0.5	0.6
Leverage (X)	2.2	2.2	2.1	2.0
Gross cash invested (ex cash) (NT\$)	367,675.4	375,013.5	385,580.8	396,345.0
Average capital employed (NT\$)	232,763.5	234,837.1	233,099.8	232,626.3
BVPS (NT\$)	83.22	92.34	107.31	130.87

Growth & Margins (%)

	12/25	12/26E	12/27E	12/28E
Total revenue growth	9.3	33.9	34.6	35.9
EBITDA growth	20.1	47.3	55.5	50.8
EPS growth	(69.8)	65.1	64.5	57.3
DPS growth	(70.0)	65.1	64.5	57.3
EBIT margin	22.4	27.0	33.3	38.6
EBITDA margin	29.8	32.8	37.9	42.0
Net income margin	17.8	21.9	26.8	31.0

Price Performance**Income Statement (NT\$ mn)**

	12/25	12/26E	12/27E	12/28E
Total revenue	132,930.0	178,007.0	239,623.0	325,553.6
Cost of goods sold	(84,800.2)	(108,294.0)	(131,520.5)	(162,106.9)
SG&A	(14,910.4)	—	—	—
R&D	(3,418.7)	0.0	0.0	0.0
Other operating inc./exp.)	0.0	(21,733.7)	(28,310.9)	(37,901.0)
EBITDA	39,634.5	58,384.2	90,766.9	136,848.9
Depreciation & amortization	(9,833.8)	(10,404.9)	(10,975.3)	(11,303.1)
EBIT	29,800.7	47,979.3	79,791.6	125,545.7
Net interest inc./exp.)	1,570.7	2,878.9	4,468.1	6,738.9
Income/(loss) from associates	0.0	946.3	607.1	279.6
Pre-tax profit	31,119.7	50,303.6	81,776.7	127,203.3
Provision for taxes	(7,342.8)	(11,153.3)	(17,455.8)	(26,084.8)
Minority interest	(142.6)	(133.7)	(120.0)	(120.0)
Preferred dividends	—	—	—	—
Net inc. (pre-exceptionals)	23,634.2	39,016.5	64,200.9	100,998.6
Post-tax exceptionals	—	—	—	—
Net inc. (post-exceptionals)	23,634.2	39,016.5	64,200.9	100,998.6
EPS (basic, pre-exception) (NT\$)	11.51	19.01	31.27	49.20
EPS (diluted, pre-exception) (NT\$)	11.51	19.01	31.27	49.20
EPS (basic, post-exception) (NT\$)	11.51	19.01	31.27	49.20
EPS (diluted, post-exception) (NT\$)	11.51	19.01	31.27	49.20
DPS (NT\$)	6.00	9.91	16.30	25.65
Div. payout ratio (%)	52.1	52.1	52.1	52.1

Balance Sheet (NT\$ mn)

	12/25	12/26E	12/27E	12/28E
Cash & cash equivalents	81,473.5	103,351.8	134,613.8	183,622.4
Accounts receivable	30,509.6	43,892.1	59,085.1	80,273.5
Inventory	31,635.6	29,669.6	36,033.0	44,412.8
Other current assets	21,727.1	21,727.1	21,727.1	21,727.1
Total current assets	165,345.8	198,640.7	251,459.1	330,035.9
Net PP&E	65,304.8	61,959.6	58,044.0	53,800.6
Net intangibles	106,699.8	105,696.2	104,692.5	103,688.8
Total investments	45,202.5	46,148.8	46,755.9	47,035.5
Other long-term assets	8,236.2	8,236.2	8,236.2	8,236.2
Total assets	390,789.2	420,681.4	469,187.7	542,797.0
Accounts payable	18,031.4	21,093.6	25,617.7	31,575.3
Short-term debt	86,258.7	86,258.7	86,258.7	86,258.7
Short-term lease liabilities	—	—	—	—
Other current liabilities	31,789.3	39,807.8	52,936.0	72,118.0
Total current liabilities	136,079.4	147,160.1	164,812.3	189,952.0
Long-term debt	57,588.8	57,588.8	57,588.8	57,588.8
Long-term lease liabilities	—	—	—	—
Other long-term liabilities	23,124.5	23,124.5	23,124.5	23,124.5
Total long-term liabilities	80,713.2	80,713.2	80,713.2	80,713.2
Total liabilities	216,792.6	227,873.3	245,525.6	270,665.2
Preferred shares	—	—	—	—
Total common equity	170,877.8	189,555.7	220,289.7	268,639.4
Minority interest	3,118.7	3,252.4	3,372.4	3,492.4
Total liabilities & equity	390,789.2	420,681.4	469,187.7	542,797.0
Net debt, adjusted	62,374.0	40,495.6	9,233.7	(39,775.0)

Cash Flow (NT\$ mn)

	12/25	12/26E	12/27E	12/28E
Net income	23,634.2	39,016.5	64,200.9	100,998.6
D&A add-back	9,833.8	10,404.9	10,975.3	11,303.1
Minority interest add-back	142.6	133.7	120.0	120.0
Net (inc)/dec working capital	(5,002.1)	(8,354.4)	(17,032.3)	(23,610.6)
Other operating cash flow	2,254.6	(946.3)	(607.1)	(279.6)
Cash flow from operations	30,863.1	40,254.5	57,656.7	88,531.5
Capital expenditures	(6,056.0)	(6,056.0)	(6,056.0)	(6,056.0)
Acquisitions	21,996.0	—	—	—
Divestitures	1,344.3	—	—	—
Others	(21,009.6)	—	—	—
Cash flow from investing	(3,725.3)	(6,056.0)	(6,056.0)	(6,056.0)
Repayment of lease liabilities	—	—	—	—
Dividends paid (common & pref)	(10,265.2)	(12,320.1)	(20,338.7)	(33,466.9)
Inc/(dec) in debt	89,213.2	—	—	—
Other financing cash flows	(85,730.0)	0.0	0.0	0.0
Cash flow from financing	(6,782.0)	(12,320.1)	(20,338.7)	(33,466.9)
Total cash flow	20,355.9	21,878.3	31,262.0	49,008.6
Free cash flow	24,807.1	34,198.5	51,600.7	82,475.5

Source: Company data, Goldman Sachs Research estimates.

mid-to-low end capacitors is expected to tighten.

Investment view

We are positive on the company's solid position to benefit from the improving commodity MLCC pricing outlook (see [here](#)). We continue to see the ongoing shift in MLCC production toward AI grade (we expect 14/24/32% of global MLCC capacity to support AI MLCC demand in 2026/27/28E, up from 9% in 2025), which will tighten supply of commodity MLCCs, driving UTR towards full capacity (we expect the global non-AI MLCC industry utilization rate to revert to 82/97/100% in 2026/27/28E from 75% in 2025) and creating a more favorable pricing environment.

Moreover, we continue to see the company making process with AI-related products. AI-related exposure reached 16% this quarter, which is tracking ahead of previous 2026 target of 15% and is likely to trend higher going forward with the solid AI demand ahead. Products used in AI applications (including tantalum capacitors, inductors, transistors, and MLCCs) typically carry higher margin, which will further support GM expansion.

Maintain Buy on Yageo with a new 12-m TP of NT\$1,280 (down from NT\$1,490).


2Q26 overview

Yageo's 2Q26 core business was 1% lower than GSe mainly due to slower GM expansion (2Q26 GM at 38.5% vs. GSe of 40.0%) despite lower opex (at NT\$5,367mn vs. GSe of NT\$5,983mn). Total revenue is largely in line with GSe but was 4% above consensus, supported by solid growth from both standard and premium products.


Exhibit 1: 2Q26 result comp table

Yageo (2327.TW)	2Q26			QoQ		YoY		Bloomberg consensus	
P&L (NT\$mn)	Actual	GSe est.	Diff (%)	1Q26	QoQ	2Q25	YoY	Consensus	%
Revenue	44,456	44,653	0%	38,166	16%	32,771	36%	42,712	4%
Gross profits	17,116	17,844	-4%	14,542	18%	11,652	47%	16,620	3%
Operating profits	11,749	11,861	-1%	9,613	22%	7,044	67%	11,413	3%
Pre-tax income	12,223	12,431	-2%	10,325	18%	7,028	74%	11,820	3%
Net earnings	9,418	9,662	-3%	8,001	18%	4,998	88%	9,156	3%
EPS, NT\$	4.59	4.71	-3%	3.90	18%	2.43	89%	4.45	3%
Gross margin (%)	38.5%	40.0%	-1.5ppt	38.1%	0.4ppt	35.6%	2.9ppt	38.9%	-0.4ppt
EBIT margin (%)	26.4%	26.6%	-0.1ppt	25.2%	1.2ppt	21.5%	4.9ppt	26.7%	-0.3ppt
Net margin (%)	21.2%	21.6%	-0.5ppt	21.0%	0.2ppt	15.3%	5.9ppt	21.4%	-0.3ppt


Source: Company data, Goldman Sachs Global Investment Research, Bloomberg

Exhibit 2: Yageo revenue mix by channel (2Q26)


Source: Company data

Exhibit 3: Yageo revenue mix by region (2Q26)

Source: Company data

Exhibit 4: Yageo revenue mix by product (2Q26)

Source: Company data

Exhibit 5: Yageo revenue mix by application (2Q26)

Source: Company data

Earnings revisions

We revise down our 2026/27/28E earnings estimate by 10/17/14% to reflect a more conservative pricing increase assumption for both MLCC and tantalum business (revise down 2026/27/28E revenue estimates by 10/17/16%). We now expect the contribution from margin accretive product to be lower, thus revise down GPM by 1.2/0.8/0.3ppt in 2026/27/28E.

Also, we introduce our 2029E earnings estimates in this report.

Exhibit 6: Earnings revision table

Yageo P&L (NT\$ mn)	2026E New	2026E Old	Diff.	2027E New	2027E Old	Diff.	2028E New	2028E Old	Diff.	2029E New
Sales	178,007	196,765	-10%	239,623	289,671	-17%	325,554	388,445	-16%	415,133
Gross Profit	69,713	79,322	-12%	108,103	132,901	-19%	163,447	196,095	-17%	216,206
EBIT	47,979	53,735	-11%	79,792	96,350	-17%	125,546	147,002	-15%	168,549
Net Income	39,017	43,553	-10%	64,201	77,095	-17%	100,999	117,671	-14%	136,413
EPS (NT\$)	19.01	21.22	-10%	31.27	37.56	-17%	49.20	57.32	-14%	66.45
Ratio analysis										
Gross margin	39.2%	40.3%	-1.2pp	45.1%	45.9%	-0.8pp	50.2%	50.5%	-0.3pp	52.1%
EBIT margin	27.0%	27.3%	-0.4pp	33.3%	33.3%	0.0pp	38.6%	37.8%	0.7pp	40.6%
Net margin	21.9%	22.1%	-0.2pp	26.8%	26.6%	0.2pp	31.0%	30.3%	0.7pp	32.9%

Source: Company data, Goldman Sachs Global Investment Research

Valuation and risks

We reiterate our Buy rating on Yageo with a new 12m TP of NT\$1,280 (from NT\$1,490), based on the same 26x 2028E PB/ROE (which is in line with the past 10-year peak multiple), after factoring in our earnings revision.

Key downside risks: (1) weaker inventory builds from OEMs; (2) softer IT end-demand; and (3) slower-than-expected integration of Kemet/Chilisin/Telemecanique/Shibaura.

Exhibit 7: P&L table

NT\$m	1Q26	2Q26	3Q26E	4Q26E	1Q27E	2Q27E	3Q27E	4Q27E	1Q28E	2Q28E	3Q28E	4Q28E	2025	2026E	2027E	2028E	2029E
Revenue	38,166	44,456	46,818	48,568	51,959	57,351	63,626	66,687	71,382	78,894	85,960	89,318	132,930	178,007	239,623	325,554	415,133
Gross profit	14,542	17,116	18,414	19,641	22,065	25,492	29,134	31,412	34,374	39,280	43,684	46,109	48,130	69,713	108,103	163,447	216,206
Operating expense	(4,929)	(5,384)	(5,682)	(5,739)	(6,112)	(6,828)	(7,552)	(7,819)	(8,306)	(9,266)	(9,998)	(10,331)	(18,307)	(21,734)	(28,311)	(37,901)	(47,656)
Operating income	9,613	11,732	12,732	13,902	15,953	18,664	21,582	23,593	26,068	30,014	33,686	35,778	29,822	47,979	79,792	125,546	168,549
Pretax income	10,325	12,234	13,252	14,492	16,473	19,234	22,102	23,968	26,298	30,776	33,914	36,215	31,140	50,304	81,777	127,203	170,749
Taxes expense	(2,287)	(2,770)	(2,915)	(3,181)	(3,590)	(4,136)	(4,676)	(5,054)	(5,475)	(6,272)	(6,965)	(7,373)	(7,346)	(11,153)	(17,456)	(26,085)	(34,216)
Net income	8,001	9,427	10,307	11,281	12,854	15,067	17,396	18,884	20,793	24,474	26,919	28,812	23,652	39,017	64,201	100,999	136,413
EPS, NT\$	3.90	4.59	5.02	5.50	6.26	7.34	8.48	9.20	10.13	11.93	13.12	14.04	11.52	19.01	31.27	49.20	66.45

Ratio analysis and assumption																	
As % of sales																	
Gross margin	38.1%	38.5%	39.3%	40.4%	42.5%	44.4%	45.8%	47.1%	48.2%	49.8%	50.8%	51.6%	36.2%	39.2%	45.1%	50.2%	52.1%
Operating expense ratio	12.9%	12.1%	12.1%	11.8%	11.8%	11.9%	11.9%	11.7%	11.6%	11.7%	11.6%	11.6%	13.8%	12.2%	11.8%	11.6%	11.5%
Operating margin	25.2%	26.4%	27.2%	28.6%	30.7%	32.5%	33.9%	35.4%	36.5%	38.0%	39.2%	40.1%	22.4%	27.0%	33.3%	38.6%	40.6%
Net margin	21.0%	21.2%	22.0%	23.2%	24.7%	26.3%	27.3%	28.3%	29.1%	31.0%	31.3%	32.3%	17.8%	21.9%	26.8%	31.0%	32.9%
QoQ growth (%)																	
Revenue	6.1%	16.5%	5.3%	3.7%	7.0%	10.4%	10.9%	4.8%	7.0%	10.5%	9.0%	3.9%	-	-	-	-	-
Gross profit	8.4%	17.7%	7.6%	6.7%	12.3%	15.5%	14.3%	7.8%	9.4%	14.3%	11.2%	5.6%	-	-	-	-	-
Operating income	9.8%	22.0%	8.5%	9.2%	14.8%	17.0%	15.6%	9.3%	10.5%	15.1%	12.2%	6.2%	-	-	-	-	-
Net income	18.2%	17.8%	9.3%	9.4%	13.9%	17.2%	15.5%	8.6%	10.1%	17.7%	10.0%	7.0%	-	-	-	-	-
YoY growth (%)																	
Revenue	22.7%	35.7%	41.5%	35.0%	36.1%	29.0%	35.9%	37.3%	37.4%	37.6%	35.1%	33.9%	9%	34%	35%	36%	28%
Gross profit	31.2%	46.9%	53.8%	46.4%	51.7%	48.9%	58.2%	59.9%	55.8%	54.1%	49.9%	46.8%	15%	45%	55%	51%	32%
Operating income	48.7%	66.6%	68.4%	58.8%	66.0%	59.1%	69.5%	69.7%	63.4%	60.8%	56.1%	51.6%	27%	61%	66%	57%	34%
Net income	44.7%	88.6%	62.2%	66.7%	60.7%	59.8%	68.8%	67.4%	61.8%	62.4%	54.7%	52.6%	22%	65%	65%	57%	35%

Source: Company data, Goldman Sachs Global Investment Research

Investment thesis and Valuation & Risks

Yageo, as the third largest MLCC and largest resistor / tantalum capacitor supplier globally, should see a stronger than peers earnings growth in the future, underpinned by better pricing environment, product upgrade, expansion strategy and more diversified product portfolio given the recent Kemet, Chilisin and Shibaura acquisitions. Yageo continues to penetrate into the high-end MLCC market (especially automotive/EV, industrial and high-end computing), which has a better S/D outlook compared to the commoditized market. Also, high-end MLCC market demand visibility is much clearer, with a more stable pricing trend, which suggests a less volatile earnings outlook. Yageo has started to benefit from an improving pricing environment for low-end MLCCs, driven by tightening supply. We hold a positive view on Yageo, given it is the supplier with the broadest product portfolio, which should help the company increase its market share by cross-selling and up-selling. Valuation offers attractive risk-reward with shares trading below historical multiples. Key downside risks: (1) weaker inventory builds from OEMs; (2) softer IT end-demand; and (3) slower-than-expected integration of Kemet/Chilisin/Telemecanique/Shibaura.

Our 12m TP of NT\$1,280 is based on a 26x average 2028E PB/ROE (in-line with the peak valuation historically and is in-line with JP peers' average 2027/28E PB/ROE). Key downside risks: (1) weaker inventory builds from OEMs; (2) softer IT end-demand; and (3) slower-than-expected integration of Kemet/Chilisin/Telemecanique/Shibaura.

Disclosure Appendix

Reg AC

We, Chao Wang, Allen Chang, Daiki Takayama and Al Wang, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Chao Wang Goldman Sachs (Asia) L.L.C., Taipei Branch, Allen Chang Goldman Sachs (Asia) L.L.C., Daiki Takayama Goldman Sachs Japan Co., Ltd., Al Wang Goldman Sachs (Asia) L.L.C., Taipei Branch.

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for Yageo Corp. is/are relative to the other companies in its/their coverage universe: AWSC, Airtac International Group, Co-Tech Development Corp., Delta Electronics, Elite Material, GCE, Hiwin Corp., ITEQ Corp, Kinsus, Lotes, NYPCB, Taiwan Union Technology Corp., Unimicron Technology, Win Semiconductors Corp., Yageo Corp., Zhen Ding Technology Holding

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs beneficially owned 1% or more of common equity (excluding positions managed by affiliates and business units not required to be aggregated under US securities law) as of the month end preceding this report: Yageo Corp. (NT\$507.00)

Goldman Sachs has received compensation for investment banking services in the past 12 months: Yageo Corp. (NT\$507.00)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Yageo Corp. (NT\$507.00)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: Yageo Corp. (NT\$507.00)

Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: Yageo Corp. (NT\$507.00)

Goldman Sachs had a non-securities services client relationship during the past 12 months with: Yageo Corp. (NT\$507.00)

Distribution of ratings/investment banking relationships


Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution				Investment Banking Relationships		
	Buy	Hold	Sell		Buy	Hold	Sell
Global	50%	34%	16%		65%	59%	43%

As of July 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,104 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the

purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

Target price history table(s)

Yageo Corp. (2327.TW)

Date of report	Target price (NT\$)	Closing price (NT\$)
05-Jul-26	1,490.00	1,045.00
15-Apr-26	346.00	322.00
26-Feb-26	302.00	298.00
31-Oct-25	265.00	249.00
17-Apr-25	600.00	114.25
27-Feb-25	660.00	141.50
30-Oct-24	693.00	139.50
30-Jul-24	850.00	152.74
03-Jul-24	825.00	152.95
18-Apr-24	720.00	124.08
29-Feb-24	695.00	116.75
03-Jan-24	715.00	120.94
26-Oct-23	625.00	106.71

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such

advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: <https://www.goldmansachs.com/worldwide/india/research-analyst>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based

in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International (“GSI”), authorised by the Prudential Regulation Authority (“PRA”) and regulated by the Financial Conduct Authority (“FCA”) and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE (“GSBE”) is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst’s judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst’s published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst’s fundamental equity rating for such stocks, which rating reflects a stock’s return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts’ fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst’s fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit,

or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.